What Is Epstein-Barr Virus, and Why Is It Linked to Multiple Sclerosis Research? - Learn about Herpes

Nearly everyone encounters Epstein-Barr virus at some point in life, usually through ordinary everyday contact.

TL;DR

Epstein-Barr virus (EBV) is human herpesvirus 4 (HHV-4), part of the same viral family as HSV-1 and HSV-2. Around 90% of adults worldwide carry it for life, usually after an infection in childhood that caused no symptoms at all. Because EBV stays latent in the body indefinitely, scientists are now studying that lifelong presence as a possible trigger for multiple sclerosis (MS).

Key Takeaways

Epstein-Barr virus (EBV) is officially named human herpesvirus 4 (HHV-4), one of eight herpesviruses known to infect humans, alongside HSV-1, HSV-2, and varicella-zoster virus.
Roughly 90% of adults worldwide carry EBV, and most people are infected during childhood without ever noticing symptoms.
Once EBV establishes latency inside B cells, it stays in the body for life, the same general pattern by which HSV-1 and HSV-2 remain latent in nerve cells.
Infectious mononucleosis (“mono”) is EBV’s most recognizable illness, but having had mono does not mean someone will develop multiple sclerosis (MS): the large majority of people who carry EBV never develop MS.
2026 research has mapped specific immune mechanisms connecting EBV to MS, but genetics and other factors still determine who actually develops the disease.

If you’ve had mono, or simply grew up hearing it called “the kissing disease,” you’ve already met Epstein-Barr virus (EBV) – you just may not know it by name. EBV rarely gets discussed the way HSV-1 and HSV-2 do, even though it belongs to the same viral family and infects a similarly enormous share of the population. Most people carry it quietly for their entire lives.

That changed somewhat in 2026, when new research gave scientists a much clearer picture of how EBV might be connected to multiple sclerosis (MS), a chronic disease affecting the brain and spinal cord. Before getting into that research, it helps to understand what EBV actually is, how common it is, and why a virus almost everyone carries rarely causes any noticeable problems at all.

What Kind of Virus Is Epstein-Barr Virus?

Epstein-Barr virus is the common name for human herpesvirus 4 (HHV-4), one of eight herpesviruses known to infect humans. The others are HSV-1 and HSV-2 (the viruses typically discussed on this site), varicella-zoster virus (which causes chickenpox and shingles), human cytomegalovirus, and human herpesviruses 6, 7, and 8 (Siakallis et al., Antiviral Therapy, 2009, DOI: 10.3851/IMP1467). All eight share a defining trait: after the first infection, they don’t fully clear from the body. Instead, they settle into a latent state – present, but largely inactive – and can persist for the rest of a person’s life.

EBV belongs to a specific branch of that family, the gamma-herpesviruses, distinguishing it from HSV-1 and HSV-2, which belong to the alpha-herpesvirus branch. The branches share the habit of lifelong latency but differ in which cells they prefer to hide in and how they typically affect the body.

Epstein-Barr virus is one of eight herpesviruses known to infect humans, each with its own behavior and preferred hiding place in the body.

How Common Is EBV, and How Do People Get Infected?

EBV infects approximately 90% of adults worldwide, making it one of the most widespread viruses in existence (Dunmire, Verghese & Balfour, Journal of Clinical Virology, 2018, DOI: 10.1016/j.jcv.2018.03.001). It spreads primarily through saliva – sharing drinks or utensils, or through kissing – which is where the nickname “the kissing disease” comes from. A global seroprevalence study found that infection typically happens far earlier than most people realize: in some regions, over a third of children are already infected by age two, and by adolescence, close to 100% of the population has encountered the virus (Tantipraphat et al., American Journal of Tropical Medicine and Hygiene, 2025, DOI: 10.4269/ajtmh.24-0857).

When EBV infection happens in early childhood, it’s almost always asymptomatic. When it happens later (commonly in the teenage or young adult years), it more often causes infectious mononucleosis, an illness marked by extreme fatigue, sore throat, swollen lymph nodes, and sometimes an enlarged spleen. Symptoms can take up to six weeks to appear after exposure, and the illness itself may last several weeks (Dunmire, Verghese & Balfour, 2018). Even among people who develop mono, the illness resolves on its own in the vast majority of cases.

What Happens After the Initial Infection? Latency, Explained

Once EBV infects the body, it doesn’t stay in an active, replicating state. It moves into B cells (a type of white blood cell that’s part of the immune system) and settles into latency, expressing only a small number of viral proteins instead of the full set it uses to actively replicate. Researchers describe several distinct latency programs, ranging from the most restrictive (expressing only one protein, EBNA1) to more active programs that express a broader panel of viral genes (Kong & Giulino-Roth, Frontiers in Immunology, 2024, DOI: 10.3389/fimmu.2024.1342455). This is conceptually similar to how HSV-1 and HSV-2 settle into latency inside nerve cells rather than fully clearing – different cell type, same underlying strategy of persistence.

Because EBV is latent rather than gone, it can periodically reactivate – becoming briefly, partially active again – usually without causing any symptoms or requiring any treatment. This lifelong, low-level presence is exactly what has made EBV a subject of growing research interest well beyond mono itself.

Once EBV settles into latency, it stays quietly present in the body without causing ongoing symptoms.

Why Are Scientists Studying EBV as a Possible Multiple Sclerosis Trigger?

The idea that EBV might play a role in multiple sclerosis (MS) isn’t new, but the evidence became substantially harder to dismiss in 2022, when a landmark study followed more than 10 million young adults in the US military over two decades. Risk of developing MS increased 32-fold following EBV infection, while infection with other common viruses, including cytomegalovirus, showed no comparable increase (Bjornevik et al., Science, 2022, DOI: 10.1126/science.abj8222). That scale of association is unusual in medicine and is part of why EBV is now widely described as a required trigger for MS.

Two 2026 studies have since added mechanistic detail to that picture. A February 2026 study found that a specific type of immune cell trained to recognize EBV (the CD8+ T cell) was concentrated in the cerebrospinal fluid of MS patients at levels 10 to 100 times higher than in their blood, suggesting localized immune activity inside the central nervous system itself (Hayashi et al., Nature Immunology, 2026, DOI: 10.1038/s41590-025-02412-3). A July 2026 study found that immune cells targeting EBV’s active-replication proteins were roughly twice as active in MS patients as in healthy people, and that reducing the number of EBV-infected B cells with existing MS therapy calmed that immune response (Bjornevik et al., Science Translational Medicine, 2026, DOI: 10.1126/scitranslmed.adz6566).

None of this means EBV alone explains MS, and having had mono is not a predictor of future MS. Roughly 90% of adults carry EBV; only a small fraction ever develop MS. Researchers studying the genetics behind MS have identified more than 230 genetic variants associated with susceptibility, and current research focuses on how those variants interact with EBV exposure and other factors, rather than treating EBV as acting alone (Jacobs et al., Brain, 2026, DOI: 10.1093/brain/awag111). EBV appears to be a necessary piece of the puzzle for most people who develop MS, not a sufficient one on its own.

2026 research is mapping the immune mechanisms that connect EBV to multiple sclerosis, one careful study at a time.

Frequently Asked Questions

Does everyone who gets mono develop Epstein-Barr virus for life?

Yes. Mono is caused by EBV, and like all herpesviruses, EBV does not fully leave the body after the initial infection. It settles into a latent state inside B cells and typically stays there for life without causing further symptoms. This is normal and expected: it does not mean an ongoing illness or a weakened immune system.

If I’ve had mono, does that mean I’ll develop multiple sclerosis?

No. Roughly 90% of adults worldwide carry EBV, and only a small fraction ever develop MS. EBV infection is considered a required trigger for MS in current research, but it is not the sole cause: genetics and other factors determine who is actually affected. Having had mono is common and, on its own, tells you very little about future MS risk.

How is Epstein-Barr virus related to HSV-1 and HSV-2?

EBV, HSV-1, and HSV-2 are all part of the same herpesvirus family, but they belong to different branches within it. All three establish lifelong latency after the first infection, but EBV persists mainly in B cells and is spread primarily through saliva, while HSV-1 and HSV-2 persist in nerve cells and are spread primarily through skin-to-skin or mucosal contact.

Can Epstein-Barr virus reactivate later in life?

Yes. Like other latent herpesviruses, EBV can reactivate periodically throughout life, usually without any noticeable symptoms. Reactivation is generally a normal part of carrying a latent herpesvirus rather than a sign that something is wrong.

Is there a vaccine for Epstein-Barr virus?

No EBV vaccine is currently approved for any use. Developing one has been difficult in part because so much remains unknown about how the immune system responds to EBV during the earliest stages of infection, though this remains an active area of research.

What This Means for Understanding EBV

Epstein-Barr virus is one of the most common viruses in existence, carried by roughly 9 out of 10 adults worldwide, almost always without any lasting problems. Its lifelong latency inside B cells is what makes it a durable, quiet presence in the body, and that same durability is what’s made it a compelling subject of 2026 immunology research into multiple sclerosis. Understanding EBV this way, as an extremely common and usually harmless part of most people’s biology, is the same lens worth applying to any herpesvirus: near-universal, generally manageable, and not something to carry shame or fear about.

For those managing herpes simplex specifically, some of the same immune-supportive habits people use for HSV – like L-lysine and monolaurin – come up in conversations about general antiviral wellness, though EBV-specific evidence for these is limited; more on how those are typically discussed can be found at Shop Monolaurin.

Continue Exploring

References

Siakallis G, Spandidos DA, Sourvinos G. “Herpesviridae and novel inhibitors.” Antiviral Therapy. 2009;14(8):1051-1064. DOI: 10.3851/IMP1467
Dunmire SK, Verghese PS, Balfour HH Jr. “Primary Epstein-Barr virus infection.” Journal of Clinical Virology. 2018;102:84-92. DOI: 10.1016/j.jcv.2018.03.001
Tantipraphat L, Sudhinaraset N, Thongmee T, et al. “Epstein-Barr Virus Seroprevalence in Thailand: A Temporal and Global Perspective with Health Care and Economic Correlations.” American Journal of Tropical Medicine and Hygiene. 2025;113(1):86-93. DOI: 10.4269/ajtmh.24-0857
Kong IY, Giulino-Roth L. “Targeting latent viral infection in EBV-associated lymphomas.” Frontiers in Immunology. 2024;15:1342455. DOI: 10.3389/fimmu.2024.1342455
Bjornevik K, Cortese M, Healy BC, et al. “Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.” Science. 2022;375(6578):296-301. DOI: 10.1126/science.abj8222
Hayashi F, Mittl K, Dandekar R, et al. “Antigen specificity of clonally enriched CD8 T cells in multiple sclerosis.” Nature Immunology. 2026;27(3):490-502. DOI: 10.1038/s41590-025-02412-3
Bjornevik K, Mahler JV, Bilodeau PA, et al. “CD4 T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.” Science Translational Medicine. 2026;18(858):eadz6566. DOI: 10.1126/scitranslmed.adz6566
Jacobs BM, Vandebergh M, Maltby VE, Dobson R, Kreft KL. “Interplay between genetic and environmental risk factors in multiple sclerosis: what have we learned?” Brain. 2026;149(8):2619-2628. DOI: 10.1093/brain/awag111